drugset / Trial / NCT05060068

Effect of Intravenous S-ketamine on Opioid Consumption

NCT05060068

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Female patients with an American Society of Anesthesia (ASA) physical status I-II, scheduled for elective breast cancer surgery will be included in the study. Subjects will be randomly assigned to one of three groups: the placebo group, the low-dose S-ketamine group, and the high-dose S-ketamine group. The primary outcome is the consumption of sufentanil during the surgery.

Timeline

Start
2021-10-07
Primary completion
2024-07-07
Completion
2024-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 2 ug/kg Intravenous
Subject Esketamine Other / unclassified 4 ug/kg Intravenous

Indications